Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers

Chemotherapy

Volumn 53, Issue 6, 2007, Pages 402-406

  Akhan, Sila Cetin ^a   Yulugkural, Zerrin ^a   Vahaboglu, Haluk ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

HBsAg titer; Interferon therapy; Precore mutant

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MUTANT; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE; VIRUS STRAIN;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CARRIER STATE; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; DNA, VIRAL; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED;

EID: 36049009997     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000109770     Document Type: Article

References (25)

1. Craxi A, Antonucci G, Camma C: Treatment options in HBV. J Hepatol 2006;44(suppl 1):S77-S83.
2. Guan R: Treatment of chronic hepatitis B infection using interferon. Med J Malaysia 2005;60:28-33.
3. Seo Y, Yoon S, Hamano K, Nakaji M, Yano Y, Katayama M, Ninomiya T, Hayashi Y,Kasuga M: Response to interferon-alpha in chronic hepatitis B with and without precore mutant strain detected by mutation site-specific assay. J Clin Gastroenterol 2004;38:460-464.
4. Yuen M, Wong DK, Sablon E, Tse E, Ng IO, Yuan H, Siu C, Sander TJ, Bourne EJ, Hall JG, Condreay LD, Lai C: HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004;39:1694-1701.
5. Zonneveld M, Honkoop P, Hansen BE, Niesters HGM, Murad SD, Man RA, Schalm SW, Janssen HLA: Long-term follow-up alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004;39:804-810.
6. Dienstag JL: Chronic viral hepatitis; in Mandell GL, Bennett JE, Dolin R (eds): Principles and Practice of Infectious Diseases, ed 6. Philadelphia, Churchill-Livingstone, 2005, pp 1441-1464.
7. Chen CH, Lee CM, Lu SN, Chen CH, Changchien CS, Wang JC, Wang JH, Hung CH, Hu TH: Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy. J Hepatol 2006;44:76-82.
8. 3 and interferon-α on FO myeloma cells. Chemotherapy 2004;50:190-193.
9. Adalati R, Gürer ÜS, Çevikba? A, Johansson C: In vitro effect of amikacin, imipenem, cefodizime, IFNα-2a alone and combinations of antibiotics with IFNα-2a on polymorphonuclear leukocyte function in chronic hepatitis patients. Chemotherapy 2001;47:261-265.
10. Mahoney FJ: Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999;12:351-366.
11. ter Borg MJ, Janssen HLA: Interferon-alpha for chronic hepatitis B; in Buti M, Esteban R (eds): Hepatitis B, ed 1. Barcelona Permanyer Publications, 2005, pp 59-68.
12. Asselah T, Ripault MP, Castelnau C, Giuily N, Boyer Marcellin P: The current status of antiviral therapy of chronic hepatitis B. J Clin Virol 2005;S115-S124.
13. Mailliard ME, Gollan JL: Emerging therapeutics for chronic hepatitis B. Annu Rev Med 2005;57:155-166.
14. Taikawa K: Recent advances in antiviral agents: antiviral drug discovery for hepatitis viruses. Curr Pharmac Design 2006;12:1371-1377.
15. Marcellin P, Asselah T, Boyer N: Treatment of chronic hepatitis B; in Thomas H, Lemon S, Zuckerman A (eds): Viral Hepatitis, ed 3. Oxford, Blackwell Publishing, 2005, pp 323-336.
16. Craxi A, Antonucci G, Camma C: Treament options in HBV. J Hepatol 2006;44(1 suppl):S77-S83.
17. van der Eijk AA, Niesters HG, Hansen BE, Heijtink RA, Janssen HL, Schalm SW, de Man RA: Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha. J Viral Hepatol 2006;13:96-103.
18. Perrillo RP: Therapy of hepatitis B - viral suppression or eradication? Hepatology 2006;43:S182-S193.
19. Lampertico P, Del Ninno E, Vigano M, Romeo R, Donato MF, Sablon E, Morabito A, Colombo M: Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003;38:779-780.
20. Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D: Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis 2003;23:81-88.
21. Uzun Y, Bozkaya H, Erden E, Cinar K, Idilman R, Yurdaydin C, Uzunalimoglu O: Hepatitis B core antigen expression pattern reflects the response to anti-viral treatment. J Gastroenterol Hepatol 2006;21:977-981.
22. Hadziyannis SJ, Papatheodoridis GV: Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. J Semin Liver Dis 2006;26:130-141.
23. Karabay O, Tamer A, Tahtaci M, Vardi S, Celebi H: Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial. J Microbiol Immunol Infect 2005;38:262-266.
24. Marcellin P, Lau GKK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N, for the Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group: Peginterferon Alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. NEJM 2004;351:1206-1217.
25. Lau GKK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck P, for the Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group: Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. NEJM 2005;352c2682-2695.